Prognostication is a key issue for sarcoma patients' care as it triggers the therapeutic approach including chemotherapy, which is still not standard for localized patients. Current prognostic evaluation, based on the FNCLCC grading system, has recently been improved by the CINSARC signature outperforming histology-based grading system by identifying high-risk patients in every grade, even in those considered as low. CINSARC is an expression-based signature related to mitosis and chromosome integrity with prognostic value in a wide range of cancers additional to sarcoma. First developed with frozen material, CINSARC is now coupled with NanoString technology allowing evaluation from FFPE blocks used in clinical practice. Consequently, CINSARC is currently evaluated in clinical trials with a dual objective of demonstrating the benefit of chemotherapy in sarcoma patients and testing its response prediction. Considering its overarching value in oncology, its development is welcome in any cancers where the prognostication needs to be improved.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/gcc.22703 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Genomic profile analysis of leiomyomas with bizarre nuclei and fumarate hydratase deficient leiomyomas: Strengths, weaknesses, and limitations of array-CGH interpretation.
Genes Chromosomes Cancer
March 2024
Oncosarc, INSERM UMR1037, Cancer Research Center, Toulouse, France.
Article Synopsis
- A study was conducted on the genomic profiles of uterine smooth muscle tumors, focusing on two types: fumarate hydratase deficient leiomyomas and leiomyomas with bizarre nuclei, to understand their relationship with clinical outcomes.
- All patients in the study were alive without disease after an average follow-up of 87.3 months, leading to the conclusion that certain genomic indices (GI) were not reliable indicators of malignancy in these tumor types.
- The research identified three groups of tumors based on genomic alterations and their associated GIs, suggesting that a GI less than 10 indicates benignity, while a GI greater than 10 does not necessarily indicate malignancy, offering a new diagnostic approach for these tumors
Deciphering the correlation between metabolic activity through 18F-FDG-PET/CT and immune landscape in soft-tissue sarcomas: an insight from the NEOSARCOMICS study.
Biomark Res
January 2024
SARCOTARGET Team, Bordeaux Institute of Oncology (BRIC) INSERM U1312, Bordeaux, F-33076, France.
Metabolic elevation in soft-tissue sarcomas (STS), as documented with F-Fluorodeoxyglucose positron emission tomography (F-FDG-PET/CT) has been linked with cell proliferation, higher grade, and lower survivals. However, the recent diagnostic innovations (CINSARC gene-expression signature and tertiary lymphoid structure [TLS]) and therapeutic innovations (immune checkpoint inhibitors [ICIs]) for STS patients underscore the need to re-assess the role of 18F-FDG-PET/CT. Thus, in this correspondence, our objective was to investigate the correlations between STS metabolism as assessed by nuclear imaging, and the immune landscape as estimated by transcriptomics analysis, immunohistochemistry panels, and TLS assessment.
View Article and Find Full Text PDFThe spectrum and significance of secondary (co-occurring) genetic alterations in sarcomas: the hallmarks of sarcomagenesis.
J Pathol
August 2023
Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH, USA.
Bone and soft tissue tumors are generally classified into complex karyotype sarcomas versus those with recurrent genetic alterations, often in the form of gene fusions. In this review, we provide an overview of important co-occurring genomic alterations, organized by biological mechanisms and covering a spectrum of genomic alteration types: mutations (single-nucleotide variations or indels) in oncogenes or tumor suppressor genes, copy number alterations, transcriptomic signatures, genomic complexity indices (e.g.
View Article and Find Full Text PDFCINSARC signature outperforms gold-standard TNM staging and consensus molecular subtypes for clinical outcome in stage II-III colorectal carcinoma.
Mod Pathol
December 2022
Oncogenesis of Sarcomas, INSERM UMR1037, Cancer Research Centre of Toulouse, Toulouse, France.
Article Synopsis
- * A new 67-gene expression prognostic signature called CINSARC has been developed, which has shown effectiveness in predicting outcomes across various cancers and can be used on preserved tissue samples through NanoString® technology.
- * In studies of CRC patients, CINSARC effectively differentiated between groups with different survival rates, demonstrating strong prognostic capacity that surpasses traditional TNM staging and CMS classification, making it a valuable tool for clinical practice.
CINSARC in high-risk soft tissue sarcoma patients treated with neoadjuvant chemotherapy: Results from the ISG-STS 1001 study.
Cancer Med
January 2023
Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Background: The Complexity INdex in SARComas (CINSARC) is a transcriptional signature derived from the expression of 67 genes involved in mitosis control and chromosome integrity. This study aims to assess CINSARC value of in an independent series of high-risk patients with localized soft tissue sarcoma (STS) treated with preoperative chemotherapy within a prospective, randomized, phase III study (ISG-STS 1001).
Patients And Methods: Patients with available pre-treatment samples, treated with 3 cycles of either standard (ST) preoperative or histotype-tailored (HT) chemotherapy, were scored according to CINSARC (low-risk, C1; high-risk, C2).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!